This biotech stock is a bargain
Options expert Stacey Gilbert explains why Celgene is trading at a discount to its peers.
Investors have been flocking to biotech stocks this year, with the IBB, the ETF that tracks biotech stocks, up nearly 16 percent. But with high returns come high valuations, except in one name, according to a strategist who closely watches the […]
Mergers & acquisitions once again took center stage in the biotech sector with Alexion (ALXN – Analyst Report) announcing its intention to acquire Synageva (GEVA – Snapshot Report). Meanwhile, there were some important updates on the regulatory and pipeline front from companies like Vertex (VRTX – Analyst Report) and Orexigen (OREX – Analyst Report).Recap of the Week’s Most Important Stories1. […]
I found some very interesting information when conducting research on small-cap biotech stocks. Most disturbing: Well-respected analysts recommended an abundance of small-cap biotech stocks that have since been annihilated. My job is to give readers ideas where they can start research to not only potentially make money, but to stay away from dangerous names. It’s not going to do any […]
Please choose a subscription
Breaking News
CNBC’s latest news headlines
Morning Squawk
Daily before the bell news roundup
Evening Brief
Daily recap of the day’s top headlines
Guest Alerts
Guest information & reminders for your calendar
Your Wealth
Weekly advice on managing your money
Options Action
Insight from the Options Action panelJob IndustryAdvertising/MarketingAutomotiveCommunications/PRConstruction/ManufacturingEducationFinance/Banking/InsuranceLegalMedia/EntertainmentMedical/Health CareMining/Oil/Gas/UtilitiesGov’t/Non-ProfitReal EstateRetailTechnology/ITTransportation/ShippingTravel/HospitalityOther
View article:
Are leveraged ETFs making biotech stocks sick? – CNBC.com
[…]
It’s been a turbulent few days for the biotech sector with the NASDAQ Biotechnology Index declining 5.46% over the last five trading days. A major part of this decline was recorded on Monday as the sector reacted to negative pipeline updates from companies like Amgen (AMGN – Analyst Report) and Celladon (CLDN – Snapshot Report). Meanwhile, Biogen’s (BIIB – Analyst […]
The biotech segment has been growing well surpassing all expectations until Monday when shares slipped significantly. The NASDAQ Biotechnology Index ^NBI and NYSE ARCA BIOTECH INDEX ^BTK had gained 16.7% and 18.7%, respectively, til Apr 24 but both declined more than 4% on Monday after disappointing news from several biotech companies.Just when news of several mergers & acquisitions, product approvals […]
Related JUNOGene Therapy Stocks Take Beating On Bad News For CelladonCAR-T Therapy Stocks Hit Hard Following AACR DataThe Real Value In MabVax May Be Partnerships Rather Than Pipeline(Seeking Alpha)While short interest in most of the leading biotechs and emerging pharmaceuticals shrank between the March 31 and April 15 settlement dates, three stocks bucked that trend.Juno Therapeutics Inc (NASDAQ: JUNO) and […]
Original article:
Biotech Stocks With Elliott-wave Forecasting | EconMatters
[…]
“That’s a high-profile move. That could make people concerned,” said Steve Massocca of Wedbush Securities. “It’s not exactly the cheapest group around. It’s got an elevated valuation here. It does nothing but go up. It doesn’t take much to create a wobble.””It doesn’t appear to be hurting other speculative areas. The social media index is up three-quarters of a percent,” […]
APActors Robert Downey Jr. and Jeremy Renner ring the opening bell Monday at the New York Stock Exchange. By Caroline ValetkevitchNEW YORK – U.S. stocks ended down Monday, led by losses in biotech shares after disappointing news from several companies including Amgen.The Nasdaq Biotech Index sank 4.1 percent, its biggest daily percentage loss since March 25, while the S&P […]
